<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176240</url>
  </required_header>
  <id_info>
    <org_study_id>Droxidopa NOH306 (306A / 306B)</org_study_id>
    <nct_id>NCT01176240</nct_id>
  </id_info>
  <brief_title>A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease</brief_title>
  <acronym>306A/306B</acronym>
  <official_title>A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chelsea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chelsea Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the effects of an investigational drug, Droxidopa, in
      participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's
      disease. Droxidopa is being studied to determine the effects on blood pressure changes upon
      standing up (orthostatic challenge). Symptoms and activity measurements, including patient
      reported falls, will be evaluated to determine the effectiveness of the study drug.

      Symptoms of NOH may include any of the following:

        -  Dizziness, light-headedness, feeling faint or feeling like you may blackout

        -  Problems with vision (blurring, seeing spots, tunnel vision, etc.)

        -  Weakness

        -  Fatigue

        -  Trouble concentrating

        -  Head &amp; neck discomfort (the coat hanger syndrome)

        -  Difficulty standing for a short time or a long time

        -  Trouble walking for a short time or a long time

      The study duration is a maximum of approximately 14 weeks including up to 2 weeks for
      screening, up to 2 weeks for proper dose finding, followed by an 8 week treatment period and
      a follow-up visit after 2 weeks. A sufficient number of patients will be screened to allow
      approximately 211 randomized patients. An extension study is also available to continue
      treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored
      by Chelsea Therapeutics and is enrolling by invitation only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systolic blood pressure is transiently and minimally decreased in healthy individuals upon
      standing. Normal physiologic feedback mechanisms work through neurally-mediated pathways to
      maintain the standing blood pressure, and thus maintain adequate cerebral perfusion. The
      compensatory mechanisms that regulate blood pressure upon standing are dysfunctional in
      subjects with orthostatic hypotension (OH), a condition that may lead to inadequate cerebral
      perfusion with accompanying symptoms of syncope, dizziness or lightheadedness, unsteadiness
      and blurred or impaired vision, among other symptoms.

      Orthostatic hypotension may be a severely disabling condition which can seriously interfere
      with the quality of life of afflicted subjects. Currently available therapeutic options
      provide some symptomatic relief in a subset of subjects, but are relatively ineffective and
      are often accompanied by severe side effects that limit their usefulness. Support garments
      (tight-fitting leotard) may prove useful in some subjects, but is difficult to don without
      family or nursing assistance, especially for older subjects. Midodrine, fludrocortisone,
      methylphenidate, ephedrine, indomethacin and dihydroergotamine are among some of the
      pharmacological interventions that have been used to treat orthostatic hypotension, although
      only midodrine is specifically approved for this indication. The limitations of these
      currently available therapeutic options, and the incapacitating nature and often progressive
      downhill course of disease, point to the need for an improved therapeutic alternative.

      Symptomatic OH in patients with Parkinson's disease is thought to be a consequence of
      norepinephrine depletion leading to low systolic blood pressure (SBP) and
      cerebral-hypoperfusion (reduced blood flow to the brain). Therapy with droxidopa results in
      increased levels of norepinephrine which should lead to improved SBP and cerebral perfusion
      thereby reducing the signs and symptoms of NOH. The present study will evaluate the clinical
      benefit in NOH patients with PD treated with droxidopa compared to those treated with
      placebo.

      Participation in the study will last a maximum of 14 weeks consisting of a 2 week (maximum)
      screening/baseline period; a 2 week (maximum) double-blind dose titration; an 8 week
      double-blind placebo-controlled treatment period; and a 2 week follow-up period. An extension
      study is also available to continue treatment if determined appropriate by the study doctor.
      This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation
      only.

      Droxidopa:

      Droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the
      International non-proprietary name (INN) for a synthetic amino acid precursor of
      norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited,
      Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve
      symptoms of orthostatic hypotension that result from a variety of conditions including Shy
      Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease.
      There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is
      biologically active. Stereoisomers and enantiomers are compounds that have the same chemical
      elements; however, they may react differently as the elements are positioned in different
      locations.

      The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been
      precisely defined; however, its NE replenishing properties with concomitant recovery of
      decreased noradrenergic activity are considered to be of major importance.

      Droxidopa has been marketed in Japan since 1989. Data from clinical studies and
      post-marketing surveillance programs conducted in Japan show that the most commonly reported
      adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In
      clinical studies, the prevalence and severity of droxidopa adverse effects appear to be
      similar to those reported by the placebo control arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The primary efficacy endpoint for 306A is the relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.
For the change from baseline, negative numbers represent improvement from baseline in OHQ score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)</measure>
    <time_frame>Baseline, Week1</time_frame>
    <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 2 (Visit 5)</measure>
    <time_frame>Baseline, Week2</time_frame>
    <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 2 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 4 (Visit 6)</measure>
    <time_frame>Baseline, Week4</time_frame>
    <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 4 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>306B Efficacy: Change in Systolic Blood Pressure (SBP) Measurements Post Standing From Baseline to Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>Measure: Lowest standing systolic blood pressure reading of immediately post standing and 3 minutes post standing. Change: standing systolic blood pressure at Week 1 (Visit 4) minus standing systolic blood pressure at baseline. A positive score indicates an improvement in standing systolic blood pressure during the double-blind randomized phase relative to value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 8 (Visit 7)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 8 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>306B Efficacy: Rate of Patient Reported Falls</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>The average number of patient reported falls per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>306B Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.
For the change from baseline, negative numbers represent improvement from baseline in OHQ score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Droxidopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>droxidopa active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droxidopa</intervention_name>
    <description>100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
    <arm_group_label>Droxidopa</arm_group_label>
    <other_name>Northera</other_name>
    <other_name>L-DOPS</other_name>
    <other_name>L-threo-dihydroxyphenylserine</other_name>
    <other_name>SM-5688</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Mannitol, Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. 18 years or over

          2. Clinical diagnosis of Parkinson's disease

          3. Clinical diagnosis of symptomatic neurogenic orthostatic hypotension

        At their baseline visit (Visit 2), patients must demonstrate:

          -  a score of at least 3 or greater on the OHQ composite

          -  a score of at least 3 or greater on the clinician CGI-S

          -  a fall of at least 20 mmHg in their systolic blood pressure, or 10 mmHg in their
             diastolic blood pressure, within 3 minutes of standing 4. Provide written informed
             consent to participate in the study and understand that they may withdraw their
             consent at any time without prejudice to their future medical care

        Exclusion Criteria:

          1. Score of 23 or lower on the mini-mental state examination (MMSE)

          2. Concomitant use of vasoconstricting agents for the purpose of increasing blood
             pressure;

             - Patients taking vasoconstricting agents such as ephedrine, dihydroergotamine, or
             midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever is
             longer) prior to their baseline visit (Visit 2) and throughout the duration of the
             study

          3. Concomitant use of anti-hypertensive medication for the treatment of essential
             hypertension

          4. Have changed dose, frequency or type of prescribed medication, within two weeks of
             baseline visit (Visit 2) with the following exceptions:

               -  Vasoconstricting agents such a ephedrine, dihydroergotamine, or midodrine

               -  Short courses (less than 2 weeks) of medications or treatments that do not
                  interfere with, or exacerbate the patient's condition under study (e.g.
                  antibiotics)

          5. Known or suspected alcohol or substance abuse within the past 12 months (DSM-IV
             definition of alcohol or substance abuse)

          6. Women who are pregnant or breastfeeding

          7. Women of child bearing potential (WOCP) who are not using at least one method of
             contraception with their partner

          8. Male patients who are sexually active with a woman of child bearing potential (WOCP)
             and not using at least one method of contraception

          9. Untreated closed angle glaucoma, or treated closed angle glaucoma that, in the opinion
             of an ophthalmologist, might result in an increased risk to the patient

         10. Sustained severe hypertension (BP ≥ 180 mmHg systolic or ≥ 110 mmHg diastolic in the
             seated or supine position which is observed in 3 consecutive measurements over an
             hour)

         11. Any significant uncontrolled cardiac arrhythmia

         12. History of myocardial infarction, within the past 2 years

         13. Current unstable angina

         14. Congestive heart failure (NYHA Class 3 or 4)

         15. Diabetic autonomic neuropathy

         16. History of cancer within the past 2 years other than a successfully treated,
             non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in
             situ

         17. Gastrointestinal condition, which in the Investigator's judgment, may affect the
             absorption of study drug (e.g. ulcerative colitis, gastric bypass)

         18. Any major surgical procedure within 30 days of the baseline visit (Visit 2)

         19. Previously treated with droxidopa

         20. Currently receiving any investigational drug or have received an investigational drug
             within 30 days of the baseline visit (Visit 2)

         21. Any condition or laboratory test result, which in the Investigator's judgment, might
             result in an increased risk to the patient, or would affect their participation in the
             study. Additionally the Investigator has the ability to exclude a patient if for any
             reason they feel the subject is not a good candidate for the study or will not be able
             to follow study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hauser, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence A. Hewitt, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Chelsea Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Schwieterman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chelsea Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology Neurodiagnostic Lab</name>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <zip>35007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Physicians of Arizona</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurology Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Health</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Neuro Specialists P.L.L.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caring Clinical Research Incorporated</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital, Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosearch - Pasadena</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Clinical Research, LLC</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosearch, Inc.</name>
      <address>
        <city>Reseda</city>
        <state>California</state>
        <zip>91335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosearch II, Inc.</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants Medical Group</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologist of Southern Connecticut, PC</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Neurology Specialists</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <zip>06040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease &amp; Movement Disorder Disoder</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates of Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies Inc.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease Treatment Center of Southwest Florida</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Research</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vero Neurology</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists of Decatur Research Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research Group</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Hospital Network</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Clinical Research</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Oaks Health System</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Vanguard Medical Associates</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Neurology</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Neurology Center, PLLC</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness and Research Center</name>
      <address>
        <city>Belvidere</city>
        <state>New Jersey</state>
        <zip>07823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdvanceMed Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shore Neurology</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research, LLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David L. Kreitzman, M.D., PC</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Neurological Associates</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parker Jewish Institute For Health Care and Rehabilitation Foundation</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040-1433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Care of CNY</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Neurology Specialists, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guilford Neurologic Associates</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America Inc</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Movement Disorder Clinic of Oklahoma PLLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ilumina Clinical Associates</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research Services LLC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JM Neuroscience Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Neurology Specialists</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Birkmayer W, Birkmayer G, Lechner H, Riederer P. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness. J Neural Transm. 1983;58(3-4):305-13.</citation>
    <PMID>6420517</PMID>
  </reference>
  <reference>
    <citation>Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003 Jul;18(7):738-50. Review.</citation>
    <PMID>12815652</PMID>
  </reference>
  <reference>
    <citation>Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension. 2003 Aug;42(2):136-42. Epub 2003 Jun 30. Erratum in: Hypertension. 2003 Oct;43(4):e12.</citation>
    <PMID>12835329</PMID>
  </reference>
  <reference>
    <citation>Kachi T, Iwase S, Mano T, Saito M, Kunimoto M, Sobue I. Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology. 1988 Jul;38(7):1091-4.</citation>
    <PMID>3133573</PMID>
  </reference>
  <reference>
    <citation>Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003 Aug 12;108(6):724-8. Epub 2003 Jul 28.</citation>
    <PMID>12885750</PMID>
  </reference>
  <reference>
    <citation>Yanagisawa N, Ikeda S, Hashimoto T, Hanyu N, Nakagawa S, Fujimori N, Ushiyama M. [Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease]. No To Shinkei. 1998 Feb;50(2):157-63. Japanese.</citation>
    <PMID>9513205</PMID>
  </reference>
  <reference>
    <citation>Malamut, R., Freeman, R., Gilden, J., Tulloch, J., Kaufmann, H., 2005. A multi-center, double-blind, randomized, placebo controlled, cross-over study to assess the clinical benefit of midodrine in patients with neurogenic orthostatic hypotension. Clin. Auto. Res. 15 (5) 337[abstract].</citation>
  </reference>
  <reference>
    <citation>Narabayashi, H., Nakanishi, T., Kanazawa, I., Yoshida, M., Mizuno, Y., Yanagisawa, N., Kondo, T. 1987. Clinical effects of L-threo-3,4-dihydroxyphenylserine in Parkinson's disease and Parkinson syndrome: Results of multi-center open study at 45 institutions. Yakuri To Chiryo (Jpn. Pharmacol. Ther.) 15(Suppl. 2):411 to 443.</citation>
  </reference>
  <reference>
    <citation>Sobue, I., Senda, Y., Suzuki, T., Narabayashi, I., Hirayama, K. 1987. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in Shy-Drager Syndrome and its related diseases. Shinkei Naika Chiryo [Neurol. Ther.] 4(2):199-208.</citation>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <results_first_submitted>March 18, 2014</results_first_submitted>
  <results_first_submitted_qc>April 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2014</results_first_posted>
  <disposition_first_submitted>March 27, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2013</disposition_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lightheadedness</keyword>
  <keyword>unsteadiness</keyword>
  <keyword>dizziness</keyword>
  <keyword>weak</keyword>
  <keyword>fatigue</keyword>
  <keyword>concentration</keyword>
  <keyword>head &amp; neck pain</keyword>
  <keyword>standing/walking for a short time</keyword>
  <keyword>standing/walking for a long time</keyword>
  <keyword>Neurogenic Orthostatic Hypotension</keyword>
  <keyword>falls</keyword>
  <keyword>NOH</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>weakness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Post-randomization, up to 2 weeks dose titration followed by 8 wks at optimal dose.
The first 51 patients enrolled in the study were analyzed as a separate group in an interim analysis (Study 306A).
The final 171 patients remained blinded until the end of the study and analyzed as a separate study (Study 306B).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Droxidopa</title>
          <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo matched control
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study 306A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stop due to diverse problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study 306B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Took at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="87">Two randomized patients discontinued before receiving study drug.</participants>
                <participants group_id="P2" count="84">One randomized patient discontinued before receiving study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 wk of Stable Dosing and Visit 4</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2 wk of Stable Dosing and Visit 5</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 wk of Stable Dosing and Visit 6</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Supine Hypertension</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrew prior to dosing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The population only includes those patients who were randomized and took at least one dose of study drug (n=222).
The first 51 patients enrolled in the study were analyzed as a separate group in an interim analysis (Study 306A).
The final 171 patients remained blinded until the end of the study and analyzed as a separate study (Study 306B).</population>
      <group_list>
        <group group_id="B1">
          <title>Study 306A: Droxidopa</title>
          <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
        </group>
        <group group_id="B2">
          <title>Study 306A: Placebo</title>
          <description>Placebo matched control
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Study 306B: Droxidopa</title>
          <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
        </group>
        <group group_id="B4">
          <title>Study 306B: Placebo</title>
          <description>Placebo matched control
Placebo: Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="87"/>
            <count group_id="B4" value="84"/>
            <count group_id="B5" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.2" spread="7.30"/>
                    <measurement group_id="B2" value="72.9" spread="7.76"/>
                    <measurement group_id="B3" value="72.5" spread="7.64"/>
                    <measurement group_id="B4" value="72.2" spread="7.97"/>
                    <measurement group_id="B5" value="72.4" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)</title>
        <description>The primary efficacy endpoint for 306A is the relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.
For the change from baseline, negative numbers represent improvement from baseline in OHQ score.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>LOCF was used to impute values for patients who did not have an end of study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)</title>
          <description>The primary efficacy endpoint for 306A is the relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.
For the change from baseline, negative numbers represent improvement from baseline in OHQ score.</description>
          <population>LOCF was used to impute values for patients who did not have an end of study visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.44"/>
                    <measurement group_id="O2" value="-2.1" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study 306A was initially designed as a blinded interim analysis by an independent DMC to ensure that the overall study was adequately powered. Study 306A was not powered to provide statistical significance as a stand alone study. Thus, no additional efficacy end points were prospectively defined beyond the primary end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model that includes treatment as a factor and baseline OHQ composite score as a co-variate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)</title>
        <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
        <time_frame>Baseline, Week1</time_frame>
        <population>The primary analysis was defined as those patients who completed 1 week of dosing at the identified optimal dose of study medication and completed the visit 4 (1 week) efficacy evaluation. Patients who did not have week 1 efficacy data were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)</title>
          <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
          <population>The primary analysis was defined as those patients who completed 1 week of dosing at the identified optimal dose of study medication and completed the visit 4 (1 week) efficacy evaluation. Patients who did not have week 1 efficacy data were excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="2.95"/>
                    <measurement group_id="O2" value="-1.3" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Statistical analysis plan involved a hierarchical assessment of secondary endpoints to prevent inflation of type I errors.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel statistic comparing treatment groups based on rank statistics adjusted for the covariate OHSA Item 1 value at baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>306A Efficacy: Patient Reported Falls</title>
        <description>The total number of patient reported falls during the 8 week treatment period</description>
        <time_frame>Baseline, Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306A Efficacy: Patient Reported Falls</title>
          <description>The total number of patient reported falls during the 8 week treatment period</description>
          <units>total falls per group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 2 (Visit 5)</title>
        <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 2 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
        <time_frame>Baseline, Week2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 2 (Visit 5)</title>
          <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 2 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.86"/>
                    <measurement group_id="O2" value="-1.6" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <p_value_desc>Statistical analysis plan involved a hierarchical assessment of secondary endpoints to prevent inflation of type I errors. As the first secondary endpoint was not positive, statistical analysis was not performed on additional secondary endpoints.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Mantel-Haenszel statistic comparing treatment groups based on rank statistics adjusted for the covariate OHSA Item 1 value at baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 4 (Visit 6)</title>
        <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 4 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
        <time_frame>Baseline, Week4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 4 (Visit 6)</title>
          <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 4 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="3.08"/>
                    <measurement group_id="O2" value="-1.5" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>306B Efficacy: Change in Systolic Blood Pressure (SBP) Measurements Post Standing From Baseline to Week 1</title>
        <description>Measure: Lowest standing systolic blood pressure reading of immediately post standing and 3 minutes post standing. Change: standing systolic blood pressure at Week 1 (Visit 4) minus standing systolic blood pressure at baseline. A positive score indicates an improvement in standing systolic blood pressure during the double-blind randomized phase relative to value at baseline.</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>One droxidopa patient did not complete the standing blood pressure measurements of the orthostatic standing test at visit 4 (one week of stable dosing)</population>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306B Efficacy: Change in Systolic Blood Pressure (SBP) Measurements Post Standing From Baseline to Week 1</title>
          <description>Measure: Lowest standing systolic blood pressure reading of immediately post standing and 3 minutes post standing. Change: standing systolic blood pressure at Week 1 (Visit 4) minus standing systolic blood pressure at baseline. A positive score indicates an improvement in standing systolic blood pressure during the double-blind randomized phase relative to value at baseline.</description>
          <population>One droxidopa patient did not complete the standing blood pressure measurements of the orthostatic standing test at visit 4 (one week of stable dosing)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="18.85"/>
                    <measurement group_id="O2" value="0.7" spread="20.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 8 (Visit 7)</title>
        <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 8 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The analysis was defined as those patients who completed 8 week of dosing and completed the visit 7 (8 week) efficacy evaluation. Patients who did not have week 8 efficacy data were excluded from the analysis. Of note, 2 patients completed the 8 week double blind study, but did not complete the efficacy evaluations at the final visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306B Efficacy: Change in OHSA Item 1 From Baseline to Week 8 (Visit 7)</title>
          <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 8 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
          <population>The analysis was defined as those patients who completed 8 week of dosing and completed the visit 7 (8 week) efficacy evaluation. Patients who did not have week 8 efficacy data were excluded from the analysis. Of note, 2 patients completed the 8 week double blind study, but did not complete the efficacy evaluations at the final visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="3.03"/>
                    <measurement group_id="O2" value="-1.5" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>306B Efficacy: Rate of Patient Reported Falls</title>
        <description>The average number of patient reported falls per week.</description>
        <time_frame>up to 10 weeks</time_frame>
        <population>The primary analysis was defined as those patients who completed 1 week of dosing at the identified optimal dose of study medication and completed the visit 4 (1 week) efficacy evaluation. Patients who did not have week 1 efficacy data were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306B Efficacy: Rate of Patient Reported Falls</title>
          <description>The average number of patient reported falls per week.</description>
          <population>The primary analysis was defined as those patients who completed 1 week of dosing at the identified optimal dose of study medication and completed the visit 4 (1 week) efficacy evaluation. Patients who did not have week 1 efficacy data were excluded from the analysis.</population>
          <units>falls per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.84"/>
                    <measurement group_id="O2" value="2.0" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>306B Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)</title>
        <description>The relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.
For the change from baseline, negative numbers represent improvement from baseline in OHQ score.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The primary analysis was defined as those patients who completed 8 week of dosing and completed the visit 7 (8 week) efficacy evaluation. Patients who did not have week 8 efficacy data were excluded from the analysis. Of note, 2 patients completed the 8 week double blind study, but did not complete the efficacy evaluations at the final visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>306B Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)</title>
          <description>The relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.
For the change from baseline, negative numbers represent improvement from baseline in OHQ score.</description>
          <population>The primary analysis was defined as those patients who completed 8 week of dosing and completed the visit 7 (8 week) efficacy evaluation. Patients who did not have week 8 efficacy data were excluded from the analysis. Of note, 2 patients completed the 8 week double blind study, but did not complete the efficacy evaluations at the final visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.29"/>
                    <measurement group_id="O2" value="-2.0" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Study 306A: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1) From Baseline to Week 1</title>
        <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>Last observation carried forward was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Droxidopa</title>
            <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched control
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Study 306A: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1) From Baseline to Week 1</title>
          <description>OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates improvement in symptoms during the double-blind randomized phase relative to value at baseline.</description>
          <population>Last observation carried forward was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="3.39"/>
                    <measurement group_id="O2" value="-1.6" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.238</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model that includes treatment as a factor and baseline OHQ composite score as a co-variate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Subjects with more than 1 of a given AE, the subject is counted only once for that AE. Subject with more than one AE in a system organ class (SOC), the subject is counted only once in that SOC.
Only dosed patients included in Safety Set.
Droxidopa Safety Set includes 3 patients randomized to placebo who were mistakenly dosed with droxidopa.</desc>
      <group_list>
        <group group_id="E1">
          <title>Droxidopa</title>
          <description>droxidopa active drug
Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
Droxidopa Safety set includes 3 patients randomized to placebo who were mistakenly dosed with droxidopa for short periods of time during the trial.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo matched control
Placebo: Placebo
Placebo Safety set excludes 3 patients randomized to placebo who were mistakenly dosed with droxidopa for short periods of time during the trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Chelsea Therapeutics Inc.</organization>
      <phone>704-973-4202</phone>
      <email>hewitt@chelsearx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

